Neuigkeiten zum Azathioprin bei CED

Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M; AZTEC study group. Early Azathioprine Therapy is no More Effective Than Placebo for Newly Diagnosed Crohn's Disease. Gastroenterology 2013 Jun 13. pii: S0016-5085(13)00885-8. doi: 10.1053/j.gastro.2013.06.009. [Epub ahead of print]

Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF. Early Administration of Azathioprine vs. Conventional Management of Crohn’s Disease: a Randomized Controlled Trial. Gastroenterology 2013 Apr 30. pii: S0016-5085(13)00699-9. doi: 10.1053/j.gastro.2013.04.048. [Epub ahead of print]

Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of Thiopurine. Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients Inflamm Bowel Dis 2013; 19 (7): 1404 – 1410.